Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HSK31858 in Healthy Volunteers
NCT05663593Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in bronchiectasis comparing HSK31858 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Feb 2022; status: completed.
02
Drugs
HSK31858
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT05663593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663593.